ReviewLancet (London, England)2016
Tuberculosis.
Review in Lancet (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 291 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
291 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Diagnostic performance of microRNA-29a in active pulmonary tuberculosis: a systematic review and meta-analysis.Clinics (Sao Paulo, Brazil) · 2023Pooled it
- Malnutrition assessment methods in adult patients with tuberculosis: a systematic review.BMJ open · 2021Pooled it
- The yield of tuberculosis contact investigation in low- and middle-income settings: a systematic review and meta-analysis.BMC infectious diseases · 2021Pooled it
- Global epidemiology of venous thromboembolism in people with active tuberculosis: a systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2021Pooled it
- An Optimal Diagnostic Strategy for Tuberculosis in Hospitalized HIV-Infected Patients Using GeneXpert MTB/RIF and Alere Determine TB LAM Ag.Journal of clinical microbiology · 2020Trial
- Ultrasound in managing extrapulmonary tuberculosis: a randomized controlled two-center study.BMC infectious diseases · 2020Trial
- Improvement of Nutritional Status among Tuberculosis Patients byBioMed research international · 2020Trial
- Tuberculous Cervical Lymphadenitis (Scrofula) Associated with Massive Pleural Effusion in an Immunocompetent Adult: A Rare Presentation of Extrapulmonary Tuberculosis Confirmed by GeneXpert MTB/RIF.Diagnostics (Basel, Switzerland) · 2026Article
- Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis: A cross-country validation study.PLoS medicine · 2026Article
- The evolving clinical profile of laryngeal tuberculosis: a 10-year retrospective study from a tertiary hospital in northern China.BMC infectious diseases · 2026Article
- Article
- Application of multimodal ultrasound radiomics in the diagnosis of superficial lymph node tuberculosis.BMC medical imaging · 2026Article
- Article
- Integrating pulmonary rehabilitation into post-tuberculosis care: Evidence-based rationale for policy change in high tuberculosis burden countries.Lung India : official organ of Indian Chest Society · 2026Article
- Single-cell and spatial profiling highlights TB-induced myofibroblasts as drivers of lung pathology.The Journal of experimental medicine · 2026Article
- Tracheoesophageal Fistula as a Rare Cause of Persistent Pulmonary Tuberculosis Symptoms.Annals of African medicine · 2026Article
- Integrating single-cell RNA-seq and bulk RNA-seq to identify hub pathways and diagnostic biomarkers in active pulmonary tuberculosis.BMC infectious diseases · 2026Article
- Membrane atg8ylation and autophagy in protection against Mycobacterium tuberculosis.Journal of immunology (Baltimore, Md. : 1950) · 2026Review
- Molecular epidemiology of drug resistance and transmission ofMicrobiology spectrum · 2026Article
- Prediction, lag and mixture effects of meteorology and pollutants on the incidence of pulmonary tuberculosis in Jining City, China.BMC public health · 2026Article
231 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
- Erratum issued
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
Although the worldwide incidence of tuberculosis has been slowly decreasing, the global disease burden remains substantial (∼9 million cases and ∼1·5 million deaths in 2013), and tuberculosis incidence and drug resistance are rising in some parts of the world such as Africa. The modest gains achieved thus far are threatened by high prevalence of HIV, persisting global poverty, and emergence of highly drug-resistant forms of tuberculosis. Tuberculosis is also a major problem in health-care workers in both low-burden and high-burden settings. Although the ideal preventive agent, an effective vaccine, is still some time away, several new diagnostic technologies have emerged, and two new tuberculosis drugs have been licensed after almost 50 years of no tuberculosis drugs being registered. Efforts towards an effective vaccine have been thwarted by poor understanding of what constitutes protective immunity. Although new interventions and investment in control programmes will enable control, eradication will only be possible through substantial reductions in poverty and overcrowding, political will and stability, and containing co-drivers of tuberculosis, such as HIV, smoking, and diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.